- Home
- BYM vs ADCT Comparison
BYM vs ADCT Comparison
Compare BYM & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYM
- ADCT
- Stock Information
- Founded
- BYM 2002
- ADCT 2011
- Country
- BYM United States
- ADCT Switzerland
- Employees
- BYM N/A
- ADCT N/A
- Industry
- BYM Investment Managers
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- BYM Finance
- ADCT Health Care
- Exchange
- BYM Nasdaq
- ADCT Nasdaq
- Market Cap
- BYM 273.5M
- ADCT 241.0M
- IPO Year
- BYM N/A
- ADCT 2020
- Fundamental
- Price
- BYM $10.49
- ADCT $2.70
- Analyst Decision
- BYM
- ADCT Strong Buy
- Analyst Count
- BYM 0
- ADCT 6
- Target Price
- BYM N/A
- ADCT $7.80
- AVG Volume (30 Days)
- BYM 60.2K
- ADCT 894.9K
- Earning Date
- BYM 01-01-0001
- ADCT 08-05-2025
- Dividend Yield
- BYM 4.49%
- ADCT N/A
- EPS Growth
- BYM N/A
- ADCT N/A
- EPS
- BYM N/A
- ADCT N/A
- Revenue
- BYM N/A
- ADCT $75,817,000.00
- Revenue This Year
- BYM N/A
- ADCT $10.65
- Revenue Next Year
- BYM N/A
- ADCT $15.05
- P/E Ratio
- BYM N/A
- ADCT N/A
- Revenue Growth
- BYM N/A
- ADCT 10.49
- 52 Week Low
- BYM $9.30
- ADCT $1.05
- 52 Week High
- BYM $11.77
- ADCT $4.13
- Technical
- Relative Strength Index (RSI)
- BYM 51.19
- ADCT 46.60
- Support Level
- BYM $10.40
- ADCT $2.55
- Resistance Level
- BYM $10.62
- ADCT $2.88
- Average True Range (ATR)
- BYM 0.08
- ADCT 0.23
- MACD
- BYM 0.02
- ADCT -0.09
- Stochastic Oscillator
- BYM 51.79
- ADCT 12.46
About BYM Blackrock Municipal Income Quality Trust of Beneficial Interest
Blackrock Municipal Income Quality Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from U.S. federal income taxes, including the alternative minimum tax. The trust invests in various sectors such as transportation, utilities, health, education, corporate, housing, and others.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).